RxDoctor Payments Data

Jessica Modisette, APRN

Acute Care · Longview, TXNPI 1386393213

Payments from drug & device makers

$1,348in general payments, 2019–2025

Across 30 payments — averaging $44.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$495
  • Teva Pharmaceuticals USA, Inc.$178
  • Evoke Pharma, Inc.$157
  • Amgen$122
  • Edwards Lifesciences$111
  • Pfizer$59
  • plus $227 from 8 others

What the payments were for

  • Travel & lodging$30323%
  • Food & beverage$1,04577%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,348 in reported general payments places this provider in the 75th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$33,216
Medicare patients
273
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$57,210
JardianceEmpagliflozin26$21,695
XareltoRivaroxaban18$19,045
Repatha SureclickEvolocumab15$7,777
Ranolazine ErRanolazine42$2,920
Metoprolol Succinate124$1,687
Clonidine13$1,186
Ezetimibe77$1,089
Isosorbide Mononitrate ErIsosorbide Mononitrate113$1,021
ClopidogrelClopidogrel Bisulfate101$810
Rosuvastatin Calcium52$770
Valsartan33$700
Atorvastatin Calcium101$694
Potassium Chloride51$642
Losartan Potassium56$589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$57,21070 claims
Johnson & JohnsonXarelto$17$19,04518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,323 acute care providers in Texas.

Other acute care in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →